Amedisys (AMED) Stock Forecast, Price & News

13 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Amedisys in the last twelve months. There are currently 10 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" AMED shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AMED, but not buy additional shares or sell existing shares.
View AMED analyst ratings or view top-rated stocks.

13 brokerages have issued 1-year price targets for Amedisys' stock. Their AMED share price forecasts range from $81.00 to $165.00. On average, they expect the company's stock price to reach $109.67 in the next twelve months. This suggests a possible upside of 17.4% from the stock's current price.
View analysts price targets for AMED or view top-rated stocks among Wall Street analysts.

Amedisys' stock was trading at $83.54 at the beginning of the year. Since then, AMED shares have increased by 11.8% and is now trading at $93.40.
View the best growth stocks for 2023 here.

Amedisys saw a increase in short interest during the month of September. As of September 15th, there was short interest totaling 2,080,000 shares, an increase of 26.1% from the August 31st total of 1,650,000 shares. Based on an average daily volume of 445,800 shares, the short-interest ratio is presently 4.7 days. Currently, 6.9% of the company's shares are sold short.
View Amedisys' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, October 25th 2023.
View our AMED earnings forecast.

Amedisys, Inc. (NASDAQ:AMED) posted its earnings results on Wednesday, July, 26th. The health services provider reported $1.37 EPS for the quarter, beating the consensus estimate of $1.09 by $0.28. The health services provider had revenue of $552.97 million for the quarter, compared to analysts' expectations of $568.18 million. Amedisys had a trailing twelve-month return on equity of 14.00% and a net margin of 0.10%. The company's revenue for the quarter was down .9% on a year-over-year basis. During the same period in the prior year, the business earned $1.47 EPS.

ETFs with the largest weight of Amedisys (NASDAQ:AMED) stock in their portfolio include First Trust Merger Arbitrage ETF (MARB), SRH U.S. Quality ETF (SRHQ), SPDR S&P Health Care Services ETF (XHS) and IQ Merger Arbitrage ETF (MNA).iShares U.S. Healthcare Providers ETF (IHF).

478 employees have rated Amedisys Chief Executive Officer Paul B. Kusserow on Glassdoor.com. Paul B. Kusserow has an approval rating of 79% among the company's employees. 60.0% of employees surveyed would recommend working at Amedisys to a friend.

Based on aggregate information from My MarketBeat watchlists, some companies that other Amedisys investors own include NVIDIA (NVDA), Alibaba Group (BABA), Johnson & Johnson (JNJ), Pfizer (PFE), Adobe (ADBE), Intel (INTC), QUALCOMM (QCOM), Broadcom (AVGO), Cisco Systems (CSCO) and Home Depot (HD).

Amedisys trades on the NASDAQ under the ticker symbol "AMED."

Shares of AMED stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of AMED stock can currently be purchased for approximately $93.40.

Amedisys (NASDAQ:AMED) has a market capitalization of $3.05 billion and generates $2.22 billion in revenue each year. The health services provider earns $118.61 million in net income (profit) each year or $0.07 on an earnings per share basis.

The company employs 20,000 workers across the globe.

Amedisys' mailing address is 3854 AMERICAN WAY SUITE A, BATON ROUGE LA, 70816. The official website for the company is www.amedisys.com. The health services provider can be reached via phone at (225) 292-2031, via email at ir@amedisys.com, or via fax at 225-292-8163.